Plexin-B3 inhibitors are a class of chemical compounds that selectively interact with the Plexin-B3 receptor, a transmembrane protein belonging to the broader plexin family, which plays a critical role in various intracellular signaling pathways. Plexin-B3 is particularly significant in guiding cellular communication and cytoskeletal organization, processes that are heavily influenced by its interaction with semaphorins, which are known to modulate axon guidance and other cellular responses. Inhibitors of Plexin-B3 generally function by preventing the receptor from engaging with its natural ligands, thus disrupting its downstream signaling activities. These inhibitors are designed to interfere with the receptor's extracellular ligand-binding domain or the intracellular signaling domains, which include GTPase-activating proteins (GAPs) and guanine-nucleotide exchange factors (GEFs). By inhibiting these interactions, Plexin-B3 inhibitors effectively modulate the dynamic activities of cytoskeletal rearrangement and cell motility, which are central to processes such as morphogenesis and cellular migration.
Structurally, Plexin-B3 inhibitors vary widely, but they often contain functional groups capable of establishing strong and specific binding interactions with the receptor. These compounds may target the intracellular domains to block the receptor's interactions with downstream effectors like small GTPases (such as Rac and Rho), which are pivotal in the regulation of actin cytoskeleton remodeling. Some inhibitors are designed to modify the conformational flexibility of Plexin-B3, thus preventing its activation and altering signal transduction pathways that involve various protein complexes and kinase cascades. The complexity of these interactions highlights the role of Plexin-B3 inhibitors in investigating the receptor's involvement in cellular mechanisms such as adhesion, migration, and cytoskeletal dynamics. Researchers in molecular biology and biochemistry continue to explore Plexin-B3 inhibitors as tools to dissect intricate signaling networks that govern cellular behavior, especially in systems where precise regulation of cell morphology and movement is critical.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Cycloheximide | 66-81-9 | sc-3508B sc-3508 sc-3508A | 100 mg 1 g 5 g | $41.00 $84.00 $275.00 | 127 | |
Cycloheximide obstructs the elongation phase of mRNA translation in eukaryotic cells, leading to a reduction in Plexin-B3 protein synthesis. | ||||||
Actinomycin D | 50-76-0 | sc-200906 sc-200906A sc-200906B sc-200906C sc-200906D | 5 mg 25 mg 100 mg 1 g 10 g | $74.00 $243.00 $731.00 $2572.00 $21848.00 | 53 | |
This compound intercalates into DNA, halting the transcription process, which would result in decreased synthesis of Plexin-B3 mRNA. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
By inhibiting histone deacetylases, Trichostatin A promotes a more open chromatin structure, potentially leading to the repression of Plexin-B3 gene expression. | ||||||
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
5-Azacytidine causes DNA demethylation, which could lead to the transcriptional silencing of the Plexin-B3 gene through changes in gene promoter accessibility. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin selectively inhibits mTOR, resulting in decreased protein translation, which includes a reduction in the synthesis of Plexin-B3. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY 294002 blocks PI3K activity, leading to a decrease in downstream signaling required for the transcription and translation of Plexin-B3. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 blocks JNK activity, which is essential for the transcriptional activation of certain genes, potentially including Plexin-B3, leading to its decreased expression. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD 98059 disrupts MEK activity within the MAPK pathway, leading to a decrease in Plexin-B3 mRNA due to diminished transcriptional activation. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
By inhibiting p38 MAP kinase, SB 203580 could lead to reduced transcriptional activation of the Plexin-B3 gene, thereby decreasing its expression. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin inhibits phosphoinositide 3-kinases, leading to a decrease in cellular signaling pathways that promote Plexin-B3 expression. | ||||||